OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

BACKGROUND: REGOMA trial showed that regorafenib (REG) significantly improved OS and PFS in patients (pts) with relapsed GBM with respect to lomustine (LOM). REG showed a different toxicity profile compared to LOM. Here, we report final results of the HRQoL assessment, a secondary end point. MATERIA...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Lombardi, G, Del Bianco, P, Brandes, A, Eoli, M, Rudà, R, Ibrahim, T, Lolli, I, Pace, A, Daniele, B, Pasqualetti, F, Rizzato, S, Bergo, E, Caccese, M, Padovan, M, Soffietti, R, De Salvo, G, Zagonel, V
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
Oral Presentations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795122/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.046
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items